The UK pharma and biotech industries have warned that clarity on Brexit arrangements for medicines is needed urgently - but no deal is in sight just 13 months ahead of its official departur
Today could be a major turning point for the UK biotech sector, as changes in government policy could help channel billions of new investment into drug discovery and development.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.